Extra-telomeric functions of telomerase in the pathogenesis of Epstein-Barr virus-driven B-cell malignancies and potential therapeutic implications by Giunco, Silvia et al.
Original Citation:
Extra-telomeric functions of telomerase in the pathogenesis of Epstein-Barr virus-driven B-cell
malignancies and potential therapeutic implications
BioMed Central Ltd.
Publisher:
Published version:
DOI:
Terms of use:
Open Access
(Article begins on next page)
This article is made available under terms and conditions applicable to Open Access Guidelines, as described at
http://www.unipd.it/download/file/fid/55401 (Italian only)
Availability:
This version is available at: 11577/3277005 since: 2018-09-11T14:50:11Z
10.1186/s13027-018-0186-5
Università degli Studi di Padova
Padua Research Archive - Institutional Repository
REVIEW Open Access
Extra-telomeric functions of telomerase in
the pathogenesis of Epstein-Barr virus-
driven B-cell malignancies and potential
therapeutic implications
Silvia Giunco1, Maria Raffaella Petrara2, Manuela Zangrossi2, Andrea Celeghin2 and Anita De Rossi1,2*
Abstract
The Epstein-Barr virus (EBV) is a ubiquitous human γ-herpesvirus causally linked to a broad spectrum of both lymphoid
and epithelial malignancies. In order to maintain its persistence in host cells and promote tumorigenesis, EBV must restrict
its lytic cycle, which would ultimately lead to cell death, selectively express latent viral proteins, and establish an unlimited
proliferative potential. The latter step depends on the maintenance of telomere length provided by telomerase. The viral
oncoprotein LMP-1 activates TERT, the catalytic component of telomerase. In addition to its canonical role in stabilizing
telomeres, TERT may promote EBV-driven tumorigenesis through extra-telomeric functions. TERT contributes toward
preserving EBV latency; in fact, through the NOTCH2/BATF pathway, TERT negatively affects the expression of BZLF1, the
master regulator of the EBV lytic cycle. In contrast, TERT inhibition triggers a complete EBV lytic cycle, leading to the death
of EBV-infected cells. Interestingly, short-term TERT inhibition causes cell cycle arrest and apoptosis, partly by inducing
telomere-independent activation of the ATM/ATR/TP53 pathway. Importantly, TERT inhibition also sensitizes EBV-positive
tumor cells to antiviral therapy and enhances the pro-apoptotic effects of chemotherapeutic agents. We provide here an
overview on how the extra-telomeric functions of TERT contribute to EBV-driven tumorigenesis. We also discuss the
potential therapeutic approach of TERT inhibition in EBV-driven malignancies.
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Background
The Epstein-Barr virus (EBV) is a ubiquitous human
γ-herpesvirus infecting more than 90% of the world’s
population. Primary infection with EBV is often
asymptomatic, but it can also manifest as infectious
mononucleosis. Although EBV may infect various cell
types, such as epithelial cells and T or Natural Killer
cells, it preferably infects B lymphocytes, in which it
establishes a lifelong asymptomatic latent infection. In
immunocompromised individuals, EBV may cause a wide
range of cancers, of both hematopoietic and epithelial
origin, including Burkitt’s lymphoma (BL), Hodgkin’s
lymphoma (HL), post-transplant lymphoproliferative
disorders (PTLD), AIDS-associated lymphomas, and
nasopharyngeal and gastric carcinomas [1].
Like other γ-herpesviruses, EBV has both lytic and
latent cycles. Primary EBV infection occurs in the
oropharynx, leading to productive lytic infection of B
lymphocytes. EBV antigens promote immune recogni-
tion, inducing an EBV-specific immune response which
controls viral infection in the immunocompetent host,
and the viral lytic cycle triggers the death of the infected
cells [2]. In tumor cells, EBV expresses various sets of
latency-associated proteins with transforming properties.
The most restricted form of EBV latency (‘latency I’),
found in BL cells, is characterized by the selective
expression of EBV nuclear antigen (EBNA)-1. A second
latency program (‘latency II’), in which EBV expresses
EBNA-1 and the three latent membrane proteins (LMP-1,
LMP-2A, LMP-2B), is found in tumor cells of HL and
nasopharyngeal carcinomas. The full set of EBV-encoded
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latency proteins (‘latency III’), including the six EBNAs
(EBNA-1, − 2, −3A, -3B, -3C, and -leader protein or LP)
and the LMPs proteins, is usually present in PTLD and
AIDS-associated lymphomas [1, 3]. In addition to its
latent proteins, EBV encodes small non-polyadenylated,
non-coding double-strand RNAs, called EBV-encoded
RNAs (EBER), which are expressed in all forms of latency
and may contribute to viral pathogenesis [4]. The onco-
genic potential of EBV is highlighted by its ability to
immortalize B cells in vitro, generating continuously
proliferating lymphoblastoid cell lines (LCLs). LCLs may
constitute an in vitro model of EBV-driven malignancies
expressing the latency III program.
While latency programs predominate in EBV-driven
tumors, lytic reactivation may occur in a small fraction
of infected cells, favoring the spread of the virus [5, 6].
Lytic reactivation, induced by endogenous or exogenous
stimuli, is orchestrated by up-regulation of two EBV
immediate-early genes, BZLF1 and BRLF1 [7]. As lytic
infection promotes the death of EBV-infected cells both
in vitro and in vivo, the lytic induction strategy has been
suggested as potential therapy to induce EBV-dependent
tumor cell killing [8–10]. Triggering EBV lytic replica-
tion may be particularly effective and therapeutically
important, as EBV lytic proteins can activate antiviral
prodrugs, such as ganciclovir (GCV) or radiolabeled
nucleoside analogs, which further promote the death of
infected cells and also prevent the release of infectious
viruses [11, 12]. Thus, the combination of antivirals with
lytic cycle inducers is emerging as a promising strategy
for treating EBV-driven tumors [13–15].
The establishment of EBV latency programs promotes
cell proliferation, inhibits apoptosis, blocks viral lytic
replication, and ensures accurate and equal partitioning
of the episomal viral genome to daughter cells [16].
However, expression of latent EBV proteins is not suffi-
cient to immortalize EBV-infected cells entirely. As in
other oncogenic viruses, a critical step for EBV-driven
transformation is to overcome cellular senescence and
acquire unlimited proliferative potential. This step de-
pends on activation of mechanisms for telomere main-
tenance [17, 18]. Although it has been suggested that in
newly EBV-infected B lymphocytes telomere length can
be maintained by alternative lengthening of telomeres
(ALT) [19], only EBV-positive cells with sustained
telomerase activity become truly immortalized, and it
has been demonstrated that most EBV-driven tumors, as
well as established LCLs, are telomerase-positive. By
contrast, telomerase-negative EBV-infected cells, al-
though exhibiting a prolonged lifespan, eventually
undergo cellular senescence and terminate their lifespan
through telomere shortening [17, 18]. In addition to its
canonical role in stabilizing telomeres, current evidence
shows that telomerase reverse transcriptase (TERT), the
catalytic component of telomerase, can promote EBV-
driven tumorigenesis through extra-telomeric functions
[20–23]. Here we review the cross-talk between telomer-
ase and EBV which is essential for the viral oncogenetic
process and discuss potential therapeutic implications.
Telomere maintenance in EBV-infected cells: The
canonical role of telomerase
Telomeres are specialized DNA structures located at the
ends of chromosomes which are essential for stabilizing
chromosomes by protecting them from end-to-end
fusion and DNA degradation [24]. In human cells, telo-
meres are composed of (TTAGGG)n tandem repeats as-
sociated with telomere-binding proteins, the shelterin
complex, which form a special T-loop-like structure,
thus avoiding the ends of chromosomes being recog-
nized as double-strand DNA damage [25]. The progres-
sive loss of telomeric repeats, which occurs at each
round of DNA replication due to the inability of DNA
polymerase to replicate the 3′ end of chromosomes
completely [26], reduces the length of telomeres to a
critical size. Such critically short telomeres are no longer
protected by the shelterin complex and are recognized
as DNA double-strand breaks which trigger the DNA
damage response (DDR), resulting in cellular senescence
and apoptosis [25]. To circumvent replicative senescence
and acquire the ability to sustain unlimited replicative
potential, tumor cells must stabilize their telomeres.
Although EBV-infected B cells exhibit higher prolifera-
tive activity than resting primary B lymphocytes, very few
EBV-carrying B cells eventually progress to
immortalization: most of them reach a proliferative crisis
and end their lifespan after about 150 population-
doubling levels, according to genetic factors, including
telomere length. Soon after EBV infection, B lymphocytes
may exhibit multiple signs of telomere dysfunction and
ALT markers, including highly heterogeneous telomeres,
appearance of extra-chromosomal telomeric DNA, accu-
mulation of telomere-associated promyelocytic leukemia
nuclear bodies, and telomeric-sister chromatid exchange
[19]. This phenotype seems to be associated with EBV-
mediated displacement of shelterin proteins and
uncapping problems at telomeres, which may favor the
activation of the ALT mechanism. ALT is an inherently
imprecise recombination-based mechanism which may
fuel the chromosomal and genomic instability that
characterize newly established LCLs [19, 27]. However,
only LCLs developing strong telomerase activity overcome
cellular crises and become stably immortalized [17, 18].
Established LCLs with sustained telomerase activity show
minimal or no signs of telomere dysfunction [19], thus
revealing the prominent role of telomerase activation in
ensuring telomere integrity during EBV immortalization.
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Telomerase is a ribonucleoprotein complex containing
an internal RNA template (telomerase RNA component,
TERC) and a catalytic protein, TERT, with telomere-
specific reverse transcriptase activity. TERT, which
synthesizes de novo telomere sequences using TERC as
a template, is the rate-limiting component of the
telomerase complex, and its expression is correlated
with telomerase activity. Although TERC has broad tis-
sue distribution and is constitutively present in normal
and tumor cells, the expression of TERT is usually
repressed in normal somatic cells and is essential for un-
limited cell growth, thus playing a critical role in tumor
formation and progression [28].
Regulation of telomerase operates at several levels:
transcription, mRNA splicing, subcellular location of
each component, and assembly of TERC and TERT in
an active ribonucleoprotein. Transcription of the TERT
gene is probably the key determinant in regulating te-
lomerase activity, since TERT transcription is specifically
up-regulated in cancer cells but silent in most normal
ones. The TERT promoter reveals complex regulation
dynamics, whereby multiple transcriptional regulatory
elements play functional roles in different contexts,
either individually or interactively. TERT contains recog-
nition sequences for many important transcription fac-
tors such as TP53, P21, SP1, ETS, E2F, AP-1, HIF1A and
MYC [29]. Regulation of TERT transcription may also
involve DNA methylation, as the TERT promoter
contains a cluster of CpG sites [29]. Somatic mutations
in the promoter of the TERT gene, which increase gene
expression by creating de novo binding sites for the
ETS/TCF transcription factors, have also recently been
described [30]. At post-transcriptional level, more than
20 different TERT variants have been reported, some of
which probably play critical roles in regulating telomer-
ase activity [31]. Telomerase activity is also controlled by
post-translational modifications of the TERT protein.
Phosphorylation of the protein at critical sites along the
PI3K/AKT kinase pathway seems to be crucial for
telomerase activity and nuclear localization. Active re-
cruitment of telomerase to telomeres is a necessary
regulatory step and involves telomere-associated
shelterin proteins [32].
Studies aimed at defining the mechanism underlying
EBV-induced telomerase activation have demonstrated
that LMP-1, the major EBV oncoprotein, up-regulates
telomerase activity both in epithelial cells [33, 34] and in
B lymphocytes [35, 36]. In particular, it has been demon-
strated that LMP-1 activates TERT in nasopharyngeal
carcinoma cells through the AKT pathway [34]: in estab-
lished LCLs, LMP-1 activates TERT at transcriptional
level via the NF-κB and MAPK/ERK1/2 pathways [36].
Of interest, while in epithelial cells TERT expression is
also MYC-dependent and the mutagenesis of MYC-
responsive E-box elements in the TERT promoter in-
hibits TERT transactivation by LMP-1 [33], in B cells
TERT activation by LMP-1 is MYC-independent. In fact,
mutagenesis in NF-κB binding sites, but not in MYC
ones, inhibits LMP-1-transactivation of the TERT pro-
moter [36]. This is of particular interest, since in most
EBV-driven tumors, like the immunoblastic lymphomas
occurring in AIDS patients and early PTLD lesions,
MYC is in a germ-line configuration. In these malignan-
cies, LMP-1 probably plays an essential role in TERT
activation.
Role of TERT in switch of latent/lytic cycle of EBV
The canonical explanation for the tumor-promoting role
of telomerase is that it allows cells to escape the barrier
to unlimited replicative potential caused by telomere at-
trition. Accumulating evidence suggests that, besides its
canonical role in stabilizing telomeres, TERT also has
other biological functions, including enhancement of cell
proliferation, resistance to apoptosis, and regulation of
DDR, [37–39]. TERT can also alleviate levels of cellular
reactive oxygen species (ROS) by enhancing cellular
antioxidant defense systems, thus allowing cancer cells
to evade death stimuli [40] and can stimulate the
epithelial-mesenchymal transition and induce stemness
[41, 42].
The extra-telomeric roles of TERT have also been
described in EBV-driven lymphomagenesis. TERT
plays a critical role in establishing EBV latency and
preventing the EBV lytic cycle, thereby contributing
to transformed phenotypes. In particular, high levels
of endogenous TERT or ectopic TERT expression in
TERT-negative EBV-infected B cells prevents the
induction of the viral lytic cycle. By contrast, TERT
silencing by specific siRNA or short-hairpin (sh)RNA
induces the expression of BZLF1, EA-D and gp350
EBV lytic genes, and triggers a complete lytic cycle.
This occurs in both EBV-immortalized and fully
transformed B cells, thus supporting the concept that
TERT is a critical regulator of the balance between
viral latent and lytic cycles [20, 21]. The treatment of
primary EBV-positive BL with zidovudine (AZT), a
thymidine analog, has also been demonstrated to in-
duce the EBV lytic cycle and cell death through the
NF-κB pathway [43, 44]. As AZT may inhibit tel-
omerase activity [45], this finding further supports the
close relationship between TERT activity and the EBV
latent/lytic cycle.
Studies aimed at defining the mechanism(s) by means of
which TERT prevents the viral lytic cycle have demon-
strated the involvement of the NOTCH2/BATF pathway.
BATF is a transcription factor expressed in hematopoietic
tissues and in B cells infected with EBV [46–48]. In LCL,
BATF is a critically important survival factor being
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involved in the suppression of pro-apoptotic BIM and in
the induction of MYC [48]. Notably, BATF has been
shown to inhibit the expression of BZLF1, thus reducing
EBV lytic replication in latently infected B cells [47]. Of
interest, BATF is a target gene of the NOTCH signaling
pathway in B cells [47]. High expression of TERT in LCLs
has been shown to activate NOTCH2 at transcriptional
level through the NF-kB pathway; in turn, NOTCH2
activates BATF, which negatively affects the expression of
BZLF1, thus repressing the EBV lytic program [22]. Ac-
cordingly, pharmacological inhibition of NOTCH2 signal-
ing by γ-secretase inhibitors decreases canonical NOTCH
target genes expression, including BATF, with a concomi-
tant increase in early and late EBV lytic genes, and thus
triggers a complete lytic cycle in both LCL and EBV-
positive BL cells [22].
More recently, the impact of TERT on EBV infection
and viral gene expression has also been studied in
epithelial cells [49]. Gastric carcinoma AGS cells with
high telomerase activity show increased expression of
latent EBV genes, indicating that telomerase directly
contributes toward favoring the latency program in epi-
thelial EBV-infected cells [49]. Thus, the ability of TERT
to favor the latency program in both B lymphocytes and
epithelial EBV-infected cells further supports the crucial
role of telomerase in EBV-driven malignancies.
TERT inhibition as a therapeutic approach for EBV-driven
malignancies
Telomerase inhibitors remain an attractive approach to
target cancer cells, given the specificity of TERT expres-
sion in tumor cells. However, in theory, the time to anti-
neoplastic effectiveness of telomerase inhibitors depends
on the original length of the telomeres in cancer cells
and, apparently, these agents are effective in halting
tumor growth only after the cancer cells have shortened
their telomeres. This aspect acquires particular import-
ance in the context EBV-carrying malignancies as it has
been demonstrated that EBV-positive BL cell lines show
longer telomeres compared to EBV-negative BLs [50]
and, during the early phases of EBV-induced growth of
primary B cells, their telomeres length remain constant
or even increase [19, 27, 51].
In this scenario, the evidence of extra-telomeric
functions of TERT in cellular kinetics and resistance to
apoptosis has recently opened the door to potential telo-
mere length-independent therapeutic effects. In EBV-
driven malignancies, besides sustaining the latency pro-
gram required for the EBV-driven transformation, TERT
may promote EBV tumor progression by enhancing the
kinetics of cell proliferation. In fact, EBV-infected B cells
with sustained telomerase activity grow faster than
telomerase-negative cells [20]. Accordingly, TERT inhi-
bition results in an anti-proliferative effect, inducing an
accumulation of cells in the S phase, probably due to
dephosphorylation of 4E-BP1, an AKT1-dependent
substrate, which results in the decreased availability of
proteins needed for cell cycle progression [21]. Thus, by
slowing proliferation kinetics, TERT inhibition may
represent an appealing suppressor strategy of EBV
tumor growth.
As mentioned previously, the first mechanism by
means of which short-term inhibition of TERT may
induce cell death of EBV-transformed cells is induction
of the EBV lytic cycle. Inhibition of TERT leads to
down-regulation of BATF and up-regulation of BZLF1,
the main regulator of the viral lytic cycle. Notably, cell
death induced by TERT inhibition in EBV-positive cells
does not depend only on the induction of the EBV lytic
cycle: inhibition of TERT with short hairpin (sh)RNA in
both EBV-positive and EBV-negative BL cell lines in-
duces apoptosis via a AKT1/FOXO3/NOXA pathway
[21]. In particular, TERT silencing induces inhibition of
AKT1 kinase, which is associated with dephosphoryla-
tion/activation of the transcription factor FOXO3, an
effector of AKT1 kinase functioning in several cell
activities, including survival. In turn, FOXO3 induces
up-regulation of NOXA, a pro-apoptotic protein, the ex-
pression of which is known to be blocked by latent EBV
infection [52]. Thus, TERT inhibition can overcome the
block of NOXA up-regulation induced by EBV, favoring
cell apoptosis [21]. Notably, although pharmacological
inhibition of AKT1 does not reveal any evidence of EBV
lytic replication in EBV-positive B cells, thus indicating
that the EBV lytic cycle induced by TERT inhibition
occurs via an AKT1-independent pathway [21], the
pharmacological inhibition of NOTCH2 triggers the
EBV lytic cycle, thus confirming the critical involvement
of the NOTCH2, BATF and BZLF1 pathways in the
latent/lytic EBV cycle [22].
In EBV-positive tumor cells, the lytic cell cycle in-
duced by TERT inhibition may be exploited to sensitize
cells to antiviral drugs such as GCV. GCV is an antiviral
prodrug activated by EBV lytic protein kinase [10, 11].
Phosphorylated/activate GCV competitively inhibits both
viral and cellular DNA synthesis, thus resulting in both
cell death of infected cells and reduction of viral replica-
tion [8]. Consequently, GCV markedly enhances the
anti-proliferative and pro-apoptotic effects of TERT
inhibition in both EBV-positive LCLs and BL [21]. Thus,
the combination of antiviral drugs with strategies cap-
able of inhibiting TERT expression/activity may result in
therapeutically substantial effects in patients with EBV-
related malignancies. Consistently, as EBV lytic reactiva-
tion after TERT inhibition is mediated by the NOTCH2/
BATF pathway, GCV also enhances the apoptotic effect
of γ-secretase inhibitors which, by blocking NOTCH2/
BATF signaling, trigger viral lytic reactivation [22].
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Most recent data show that LCLs and both EBV-
positive and EBV-negative BL cells short-term treated
with BIBR1532 (BIBR), a chemical compound which
selectively inhibits the catalytic activity of TERT [53],
undergo cell cycle arrest in S phase and apoptosis
[23]. These effects are telomerase-specific and have
not been observed in telomerase-negative cell lines.
The cell cycle arrest and apoptosis subsequent to
TERT inhibition are associated with and probably
dependent on activation of the DDR pathway. TERT
inhibition does induce DDR, highlighted by increased
levels of γH2AX, activation of ATM and ATR and
their downstream substrates CHK1, CHK2 and pro-
apoptotic TP53. Notably, the DDR pathway activated
after short-term exposure to BIBR is not related to
telomere dysfunction, as BIBR treatment does not
affect the mean and range of telomere lengths and
γH2AX damage foci are randomly diffuse, rather than
being specifically located on telomeres [23]. It has
been demonstrated that the productive cycle of EBV
elicits ATM-dependent DDR, and provides an S-
phase-like cellular environment suitable for viral lytic
replication [54]. Thus, it is reasonable that, in EBV-
positive background, cell cycle arrest in S phase and
DDR activation consequent upon TERT inhibition is
partly orchestrated by the induction of the lytic cycle.
In addition, treatment of LCL with BIBR in combi-
nation with Fludarabine or Cyclophosphamide, two
agents frequently employed to treat B-cell malignan-
cies, induces a significant increase in specific cell
death compared with results seen after treatment with
chemotherapeutic agents alone. These results may
Fig. 1 TERT levels affect EBV latent/lytic status. A, cross-talk between EBV and TERT to sustain viral latency program: in EBV-infected primary B lymphocytes,
activation of TERT occurs concomitantly with induction of latent EBV proteins and down-regulation of EBV lytic gene expression. EBV-encoded LMP-1
activates TERT at transcriptional level via NF-κB and MAPK/ERK1/2 pathways. In turn, TERT expression activates NOTCH2 at transcriptional level via NF-κB
pathway. NOTCH2 activates BATF, which negatively affects the expression of BZLF1, a master regulator of viral lytic cycle, thus favouring induction and
maintenance of EBV latency program, essential for EBV-driven transformation. Immunohistochemical image: TERT (a, b) and BZLF1 (c, d) protein expression
in early- (a, c) and late- (b, d) infected B lymphocytes (X40). B, TERT or NOTCH inhibition triggers EBV lytic cycle: TERT silencing by shRNA
(shTERT) or inhibition of NOTCH signaling by γ-secretase inhibitors lead to NOTCH2-dependent down-regulation of BATF and up-regulation of BZLF1,
inducing a complete EBV lytic cycle. Immunohistochemical image: EBV lytic gp350 protein expression in EBV-positive BL cells untreated (a) and treated
(b) for 72 h with shTERT (X20). Scale bar, 100 μm. See the text for details
Giunco et al. Infectious Agents and Cancer  (2018) 13:14 Page 5 of 7
lead to the substantial clinical application of TERT
inhibitors in combination with standard chemothera-
peutic protocols to treat EBV-positive B-cell malig-
nancies [23].
Conclusions
Since a latent program is required to promote EBV tumori-
genesis, whereas the lytic cycle induces cell death, the find-
ing that TERT, besides maintaining telomere integrity, also
plays a critical role in the establishment of EBV latency and
in preventing the EBV lytic cycle (Fig. 1A), supports the
view that TERT inhibition is an appealing therapeutic stra-
tegy against EBV-driven malignancies. By triggering the
viral lytic cycle, TERT inhibition induces cell death (Fig. 1B)
and sensitizes EBV-infected cells to antiviral drugs. Notably,
besides triggering the viral lytic cycle via the NOTCH2/
BATF/BZLF1 pathway (Fig. 1B), short-term inhibition of
TERT activates pro-apoptotic programs via the AKT1/
FOXO3/NOXA and ATM/ATR/TP53 pathways. Notably,
cell cycle arrest and the pro-apoptotic effects of short-term
TERT inhibition are independent of telomere length. Thus,
in both EBV-driven and virus-unrelated B-cell malignancies
inhibition of TERT seems to be an effective approach in in-
ducing cell death, regardless of telomere length. In vitro ex-
periments also demonstrate that the therapeutic approach
based on inhibition of TERT enhances the pro-apoptotic
and anti-proliferative effects of chemotherapeutic agents in
EBV-transformed cells. Further studies of primary tumor
cells from patients with EBV-driven malignancies and suit-
able animal models will pave the way for a solidly based
pre-clinical rationale for including TERT inhibitors in
chemotherapy protocols for treating these malignancies.
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